Choosing an evidence-based workup and treatment for recurrent pregnancy loss is imperative to provide best patient care and create a culture that permits rigorous research into potential (not yet evidence-based) tests and therapeutics. As health sciences technologies become more sophisticated, more precise, and less expensive, new tools may be developed that allow better evaluation and treatment of couples with recurrent pregnancy loss. The goal must remain optimizing value and adhering to evidencebased care.
Basic Epidemiology of Recurrent Pregnancy Loss (RPL)
Failure of the conceptus to survive beyond the mid-second trimester is common, affecting 10% of clinically recognized pregnancies and 20% of unrecognized conceptions. 1 recurrent pregnancy loss (RPL), usually defined as 2 or more consecutive losses, 2 is also a frequent reproductive problem, with 5% of couples attempting pregnancy suffering 2 or more losses, and 0.5% to 1% having 3 or more. 2 Most losses that occur after the pregnancy is clinically recognized to occur in the preembryonic or embryonic period (<10 wk gestation). Death of the conceptus alive at or beyond 10 weeks, or fetal death, is a less common type of pregnancy loss. Silver et al 3 have proposed a useful algorithm for nomenclature of pregnancy loss, which is more specific than previous iterations. These definitions usedevelopmentalphasetodefinestagesof pregnancy loss. By grouping pregnancy losses by specific time frames, etiology may be easier to elucidate. When RPL is unexplained, losses tend to occur at the same gestational age period, suggesting some undefined factor specific to that period of embryonic or fetal development. 4, 5 Most practitioners recognize that among sporadic, for example, non-RPL, the majority of losses during the preembryonic or embryonic periods are due to spontaneous (and nonrecurrent) aneuploidy. However, aneuploidy is less commonly found in abortuses of women with RPL, suggesting that other etiologic factors are at play. 6, 7 Most experts agree that uterine malformations, parental karyotype abnormalities, and antiphospholipid antibodies, if present, are important etiologic factors. In otherwise healthy women, the possible roles of endocrinologic, immune, and thrombophilic factors are debated. In fact, it is very likely that most cases of RPL are multifactorial in etiology and include male partner, female partner, and embryonic factors or variables, most of which are yet to be elucidated. Clearly, advancing maternal age is a risk factor for pregnancy loss. More recently, obesity also has been identified as increasing the chances for miscarriage. 8 In 1 study of women with RPL, obese women had increased odds of having yet another pregnancy loss when compared with nonobese women [odds ratio (OR) = 1.73, 95% CI, 1.06-2.83]. 9 Women with history of pregnancy loss are also at increased risk of cardiovascular disease 10 and both renal and cardiovascular atherosclerotic morbidity. 11 Might some common risk factors be at play here? Some experts even suggest RPL may be due to a failure of embryonic ''quality control,'' with the endometrium allowing poor-quality embryos to implant and become a clinically recognized pregnancy destined to be lost. 12 It is critically important to recognize that among women with recurrent preembryonic and embryonic losses, the outcomes of subsequent pregnancies are quite positive when compared with subsequent pregnancy outcomes in women of similar age without RPL. Indeed, live birth rates exceed 70% in most couples with RPL, with even better outcomes once embryonic cardiac activity is visualized. [13] [14] [15] Both maternal age and number of previous losses alter the prognosis for the subsequent pregnancy, as outlined by Brigham et al. 16 For example, in this dataset, a 25-year-old woman with 2 previous losses has a 89% predicted success rate in a subsequent pregnancy, whereas a 40-year-year old woman with 5 previous losses has an only 42% predicted success rate. Increasing maternal age is associated with increase in embryo aneuploidy, which is the likely reason for the worsening prognosis with advancing years.
Challenges in RPL Research
Except for parental structural karyotype abnormalities,thefactorsusuallyconsidered in the evaluation of couples with RPL, and thus thought by at least some experts to be associated with RPL, lack well-understood causative mechanisms. These include autoimmune disorders, endometrial dysfunction and endometritis, 17, 18 endocrine dysfunction, thrombophilias, 19 and uterine malformations. 20, 21 A 2002 workshop by the EuropeanSocietyforHumanReproduction and Embryology noted only a small number oftrulyevidence-basedtestsforRPL.Extant studies exhibit abundant flaws, including studydesign,phenotypedefinition,choiceof controls, and failure to account for possible variation in biomarkers.
Much of the research in the field of RPL has consisted of case-control studies, where women with RPL (cases) are compared with their unaffected counterparts (controls).Exposuresarethenassessed(eg, demographic factors, genetic mutations, and biomarkers) and rates of exposures are compared between groups and reported as an OR. Case-control studies are strictly observational and are easily biased if (a) cases are not well selected, (b) controls are not appropriately defined, and (c) confounders are not accounted for. 22 Confounders are notoriously difficult to predict and account for in observational analysis, but some are well established. Maternal age, for example, is a confounder thatcanleadtoperturbationsinavarietyof biomarkers while also being a direct risk factorforpregnancyloss.Whenevaluating RPL studies, it is crucial to note whether cases are defined by 2 or 3 previous pregnancy losses and if any live births arepermitted inthe casegroup.Oneshould question whether controls are selected from the same population as women with RPL, and whether there is something intrinsically different about them, for example, availability for study or of a higher or lower socioeconomic status. Given the difficulty assessing and controlling for confounders in case-control trials, some experts in study design recommend considering any OR<3 to possibly be due to confounding and thus not a true association. 22 This should be kept in mind when assessing case-control studies of RPL.
Consider, for example, the case of skewed X-linked inactivation. The theory is that increase in skewed X-inactivation ( >90% or >95% skewed) is suggestive of X-linked recessive traits in the mother, which could be lethal in a male embryo or fetus. One study found a 14% rate of highly skewed X-inactivation in women with history of 2 or more previous losses of unexplained etiology compared with only 1% of controls. 23 Another study with similarly chosen cases and controls found no difference in skewed X-linked inactivation (2.3% in cases vs. 4.1% in controls). 24 Further work indicated that skewed Xlinked inactivation becomes more common as women age. 25 Thus, maternal age is a likely confounder to any association between skewed X-linked inactivation and RPL. To their credit, the authors of the original study (which found an association between skewed X-linked inactivation and RPL) published a follow-up study controlling for maternal age and reported that, in fact, skewed X-linked inactivation wasnotassociatedwithRPL. 26 Inthiscase, then, an association was found, studied further and ultimately found to be a confounder, not a causative factor.
In RPL studies involving biomarkers, it is important (yet challenging) to note the timing of specimen acquisition, particularly the proximity to pregnancy (for both RPL subjects and controls) and timing in themenstrualcycle.Alltooofteninstudies, samples are drawn at a time of a convenient office visit. While understandable, this is a notable confounder for any study of biomarkers affected by cyclical hormonal changes. Another potential confounder for many biomarkers often ignored in RPL studies is whether the patient was fasting or postprandial at the time of blood draw.
In older studies an all too common methodological flaw in RPL research was the use of historic controls. Often a patient is used as her own control, with her personal history used as the control group outcome. This biases the study to find the intervention to be effective. By definition, RPL patients have ahistoryofmoremiscarriagesthan live births.However,mostofthemalsoaremore likely than not to have a successful live birth in their subsequent pregnancy, with or without intervention. 13 Thus, when rates of live birth are compared before and after intervention, the intervention is almost certainly going to appear successful (unless it is, in fact, significantly harmful). Success was already likely. The error inherent in using historic controls has been demonstratedinstudiesofuterineseptum resection and preimplantation genetic diagnosis. [27] [28] [29] This is not to say that these 2 therapies might not, indeed, be efficacious. However, use of historic controls is not appropriate and should not be used to support the use of these therapies (which are both costly and potentially morbid).
To be sure,randomizedclinicaltrials are difficult to conduct in the RPL population. Patients are averse to being randomized, and clinicians have a strong desire to ''do something,'' leading to poor acceptance of randomization to placebo. Given the lack
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Gibbins and Porter www.clinicalobgyn.com of proven, standard-of-care therapies, control subjects might be expectantly managed. In addition, it is easy for patients to gain access to unproven treatments outside of well-conducted, randomized clinical trials. Even with regard to factors most compellingly associated with RPL, for example, uterine malformations or antiphospholipid antibodies, a solid understanding of causative mechanisms is lacking. This, in turn, has hampered the identification of candidate treatments. Even for proposed treatments, the elephant in the room is the relative lack of well-designed, properly powered trials. An excellent recent trial of vaginal progesterone in women with RPL is a welcome exception. This randomized women with RPL to 400 mg micronized progesterone or placebo twice a day from time of positive pregnancy test until 12 weeks' gestation and found no difference in live birth rate (65.8% in placebo group vs. 63.3% in the progesterone group). 30 Vaginal progesterone is frequently used in women with RPL, andnowwehavestrongevidencethatthisis unnecessary.
The Study and Use of Screening and Diagnostic Tests
When choosing demographic and obstetric risk factors to consider clinically relevant, it is important to recall that risk factors are only useful in predicting future outcomes if they are strongly associated with the outcome. Typically, risk factors are assessedby studyingthe odds offinding the risk factor in a population with the outcome or disease compared with the odds of finding the risk factor in a population without the outcome or disease. As ageneralrule,tobeusefulasascreeningtest the factor must be strongly associated with the disease. 31 When the affected and unaffected populations have much overlap in factorvalues (ratesof the risk factor), the predictive value is limited.
Screening tests should be evaluated by the detection rate (DR), that is, the percentage of affected individuals with a positive result, and the false-positive rate (FPR). 32 The DR and the FPR are intrinsic to the test and how a positive result is defined. The DR and FPR are unaffected by the incidence of the condition. 33 In contrast to screening tests, diagnostic tests are evaluated using the same parameters but may have different cutoffs for DR and FPR depending on the disease in question.
Wald and Cuckle 32 propose a series of questions for evaluating tests. These questions are based in part on the classic book Principles and Practice of Screening for Disease, an outline of what public health practitioners and clinicians should consider when embarking on evaluations. 34 Important questions to consider pertinent to RPL evaluation include: what are the medical costs and benefits? What are the financial costs and benefits? What therapeutic intervention will follow a positive result? What is the justification of this therapy? Although RPL is not a disease in the classic sense, nor do we screen an asymptomatic population, these questions can still guide us when determining the appropriate evidence-based workup and treatment for RPL.
Cost and Commercialization
All medical evaluations, as well as treatments, have costs. Value in health care is defined as health outcomes achieved per dollar spent. 35 One Web site lists costs of commontestsusedtoevaluatewomenwith RPL. 36 Using the low end of the range quoted for each test, the total comes to $5637. A recent cost-effectiveness analysis estimated that an evidence-based workup would cost $3551 for a self-pay patient. 33 Insurance (for those who have it) will cover some butnotallofthecostsofevaluationin the United States (parental karyotypes, for example, are frequently not covered). At Importance of Evidence-based Workup for RPL 459 www.clinicalobgyn.com the end of the costly workup, odds remain high that the woman will be left in the unexplained RPL category without a reason for her losses that she was searching for. If her subsequent pregnancy outcome is not meaningfully changed, the value of this evaluation is low. If one types ''recurrent pregnancy loss'' intoapopularonlinesearchengine,8outof 10 results on the first page are patientconsidered and clinician-considered resources-national organizations, academic institutions, and patient-created support groups. Two are private clinicians offering services. By the second page, there are more clinicians seeking patients as well as laboratories marketing propri-etarytestsforRPL.OnesuchclinicianWeb site opens with a listing of many expensive therapies with no proof of efficacy such as immunotherapy. In the upper right hand corner, there is a prominent tab for online bill pay.
There has been a proliferation of forprofit RPL centers, with many tests availableon site. Giventhatmuchofthe services rendered in these centers have not been shown to improve outcomes, these practices are predatory in nature and do not improve medical care.
Science and the Media
Themediaownsalargeresponsibilityinthe propagationoffalsehopeorhopebeforeits time for women with RPL. Recently, a robust analysis of human endometrial stromal cells (HESCs) showed that in women with RPL, the epigenetic signature of HESCs is different than that in women with normal pregnancies. 37 The authors speculate that HESCs in women with RPL are less pluripotent and conclude that this combines with deficiency of mesenchymal stem cells to diminish endometrial plasticity and lead to RPL. The popular press published this finding as the answer to miscarriage treatment, titling articles ''Scientists identify cause of multiple miscarriages for firsttime'' 38 and''Lackofstemcellstoblame for recurrent miscarriages.'' 39 One of the primary study's authors is quoted as saying: ''I can envisage thatwe willbe ableto correct these defectsy.In fact, this may be the only way to really prevent miscarriages in these cases.'' 40 These articles (all of which appear to be sourced from the same press release) paint this study of HESCs as the 1 final answertotheproblemofRPL.Ofcourseitis unclear whether this test truly predicts RPL or whether effective treatments can be developed. Although these data are novel and interesting, sensationalist journalism does not make for good science or patient care. In fact, it causes harm by creating false hope and expectations among couples with RPL.
In our experience, one of the first things women with RPL (or really any medical condition) do is an online search. Given the current state of the search results, it is not surprising that many RPL patients find the results of their search hopeful. Many then ask their clinicians whether they could receive, for example, therapeutic stem cell treatments for their RPL. This is in the absence of compelling, evidence-based, proof of effectiveness and promotes costly and potentially risky medical care. Other fields have already seen commercialization of expensive stem cell treatments without evidence of clinical benefit. 41, 42 
Dangers of Overdiagnosis
Pursuing evaluations of uncertain association, especially in the absence of credible treatments to improve outcomes adds incremental financial cost, as well as diminishesthe value ofhealthcareprovided. Such practices also have the potential to cause harm. Although the concept of overdiagnosistypicallyisdefinedasdiagnosiswithan asymptomatic disease that will not ultimately lead to significant morbidity, it is starting to be expanded. 43 There are many motivators that lead to overdiagnosis-a desire for ''an answer,'' the belief that our patientswantusto''dosomething''(andthe idea that ordering a test is ''doing something''), and the availability of commercialized, new technology. But our being able to tellawomanwithRPLthatherlevelofsome biomarker is slightly high or slightly low is not useful if that knowledge does not improve her ability to have a live birthour goals in diagnosis should be to obtain useful information that will improve treatment.
Preventing overdiagnosis is the basis of the Choosing Wisely campaign. Choosing Wisely was started by the American Board of Internal Medicine in 2012 with a goal of ''avoidingwastefulorunnecessarymedical tests, treatments, and procedures.'' 44 As part of Choosing Wisely, multiple medical specialty and subspecialty societies have submitted lists of 5 to 10 recommendations of things to avoid. Relevantly, one of the recommendations by the Society for Maternal-Fetal Medicine is, ''Don't do an inherited thrombophilia evaluation for women with histories of pregnancy lossy.'' 45 They go on to say that data linking inherited thrombophilia and adverse pregnancy outcomes are not substantial enough to warrant this testing.
What Does the Evidence Support?
The evidence for and against evaluations andtreatmentsforRPListhesubjectofthis issueofClinicalObstetricsandGynecology. We posit that choosing an evidence-based workup and treatment for RPL is imperative, to provide best patient care and to create a culture that permits rigorous research into potential (not yet evidencebased) tests and therapeutics. An article in the New York Times said it well: ''Affected couples, often desperate for a solution, sometimes grasp at unproven or useless remedies. What they need instead is factual information, emotional support and, if possible, treatment based on a medically established cause.'' 46 The evidence supporting (and questioning) this evaluation and treatments will be presented in following chapters in detail. We recognize that as health sciences technologies become more sophisticated, (hopefully) more precise, and (hopefully) less expensive, we may develop new tools that allow us to better evaluate and treat couples with RPL. As exciting as the future of reproductive medicine is, the goal must remain optimizing value and adhering to evidence-based care.
